Navidea Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor
– CEO to Provide Business and Development Program Updates –
BIO CEO & Investor Conference 2013
DUBLIN, Ohio -- February 6, 2013
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company
focused on precision diagnostic radiopharmaceuticals, today announced that Dr.
Mark Pykett, President and Chief Executive Officer, will participate at the
15^th Annual BIO CEO & Investor Conference, hosted by the Biotechnology
Industry Organization (BIO), on February 11-12 at the Waldorf-Astoria in New
York City. Dr. Pykett will provide an update of the Company and its
development programs on Monday, February 11, 2013 at 3:30 PM EST.
Investors and the public are invited to listen to a live webcast of Dr.
Pykett’s presentation at
the conference, the webcast will be archived for approximately 30 days.
About Navidea Biopharmaceuticals Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical
company focused on the development and commercialization of precision
diagnostics and radiopharmaceutical agents. Navidea is actively developing
four radiopharmaceutical agent platforms – Lymphoseek^®, NAV4694, NAV5001 and
RIGScan^TM – to help identify the sites and pathways of undetected disease and
enable better diagnostic accuracy, clinical decision-making and, ultimately,
patient care. Navidea’s strategy is to deliver superior growth and shareholder
return by bringing to market novel radiopharmaceutical agents and advancing
the Company’s pipeline through selective acquisitions, global partnering and
commercialization efforts. For more information, please visit www.navidea.com.
About the BIO CEO & Investor Conference
The 15^th Annual BIO CEO & Investor Conference is the largest independent
investor conference focused on publicly-traded biotechnology companies. This
year’s conference will feature corporate presentations from more than 140
leading biotechnology and pharmaceutical companies, Fireside Chats with
industry leaders, four Therapeutic Workshops and three Business Roundtables
all drawing from seasoned industry executives and analysts. New this year, a
special track of 25 high-caliber private companies will be presenting at the
event, and plenary sessions will address timely business issues and industry
trends. Attendees can expect many opportunities to schedule one-on-one
meetings as well as numerous networking opportunities. The conference is
designed to foster an informative dialogue between institutional investors and
senior biotechnology executives about emerging and current investment
Brent Larson, Sr. VP & CFO – (614) 822-2330
Press spacebar to pause and continue. Press esc to stop.